Matches in SemOpenAlex for { <https://semopenalex.org/work/W3120630806> ?p ?o ?g. }
Showing items 1 to 99 of
99
with 100 items per page.
- W3120630806 endingPage "S745" @default.
- W3120630806 startingPage "S744" @default.
- W3120630806 abstract "Abstract Background Suvratoxumab is a human monoclonal antibody that neutralizes S. aureus (SA) alpha toxin (AT). SAATELLITE, a phase 2 study of the safety and efficacy of suvratoxumab for reducing the incidence of SA pneumonia (NCT02296320), was conducted within the consortium for Combatting Bacterial Resistance in Europe. Methods A total of 304 SA isolates (baseline, onset and last available isolates from suspected serious bacterial infections, SSBIs) collected from the lower respiratory tract samples from 165 subjects during SAATELLITE were subjected to whole genome sequencing. AT gene (hla) sequences were translated and amino acid variation was identified in comparison to the reference SA USA300 FPR3757. Phylogenetic analysis, genomic annotation and ST analysis were performed. AT expression in SA culture supernatants was performed by ELISA. Representative isolates with novel AT subtypes that had not been identified in previous studies were tested for hemolytic activity and suvratoxumab neutralizing activity. Wilcoxon rank sum test and Fisher’s exact test were performed, respectively: a) to compare difference in baseline AT expression in relation to SA pneumonia incidence; b) to evaluate the association between occurrence of AT stop codons and incidence of SA pneumonia at baseline, as well as the association between occurrence of AT stop codons and treatment arms at post baseline. Results We identified a total of 44 sequence types (STs) and 21 unique AT subtypes, 7 of which have not been described previously. No substitutions were located in the suvratoxumab binding region and all novel AT subtypes displaying lytic activity were neutralized by suvratoxumab. We detected stop codons Q113B and W205B in AT sequences in 53 and 2 SA isolates, respectively. We uncovered no significant associations of: 1) baseline AT expression with SA pneumonia incidence [p=0.967]; 2) occurrence of AT gene stop codon with either SA pneumonia incidence [p >0.999] or suvratoxumab treatment [p=0.103; lower frequency of stop codons in suvratoxumab arm versus placebo]. Conclusion Our data indicated that: 1) suvratoxumab target region in (AT) remains conserved; 2) suvratoxumab is active against all AT variants identified to date; 3) suvratoxumab did not exert pressure on SA clinical isolates for selection of escape mutants. Disclosures David E. Tabor, PhD, AstraZeneca (Employee, Shareholder) Andrey Tovchigrechko, PhD, AstraZeneca (Employee, Shareholder)KitePharma, a Gilead company (Employee, Shareholder) Bret R. Sellman, PhD, AstraZeneca (Employee, Shareholder) Michael McCarthy, n/a, AstraZeneca (Employee) Kathryn Shoemaker, MS, AstraZeneca (Employee) Hasan S. Jafri, MD, FAAP, AstraZeneca (Employee) Mark T. Esser, PhD, AstraZeneca (Employee) Alexey Ruzin, PhD, AstraZeneca (Employee, Shareholder)" @default.
- W3120630806 created "2021-01-18" @default.
- W3120630806 creator A5006425702 @default.
- W3120630806 creator A5013873904 @default.
- W3120630806 creator A5019490903 @default.
- W3120630806 creator A5022379264 @default.
- W3120630806 creator A5024447718 @default.
- W3120630806 creator A5025385905 @default.
- W3120630806 creator A5036202060 @default.
- W3120630806 creator A5041651603 @default.
- W3120630806 creator A5049655890 @default.
- W3120630806 creator A5050859911 @default.
- W3120630806 creator A5053583356 @default.
- W3120630806 creator A5064047605 @default.
- W3120630806 creator A5067042263 @default.
- W3120630806 creator A5069122156 @default.
- W3120630806 creator A5080750886 @default.
- W3120630806 creator A5081704353 @default.
- W3120630806 creator A5081967303 @default.
- W3120630806 date "2020-10-01" @default.
- W3120630806 modified "2023-10-15" @default.
- W3120630806 title "1486. Phylogenetic and alpha toxin variant analyses of Staphylococcus aureus strains isolated from patients during the SAATELLITE study" @default.
- W3120630806 doi "https://doi.org/10.1093/ofid/ofaa439.1667" @default.
- W3120630806 hasPublicationYear "2020" @default.
- W3120630806 type Work @default.
- W3120630806 sameAs 3120630806 @default.
- W3120630806 citedByCount "0" @default.
- W3120630806 crossrefType "journal-article" @default.
- W3120630806 hasAuthorship W3120630806A5006425702 @default.
- W3120630806 hasAuthorship W3120630806A5013873904 @default.
- W3120630806 hasAuthorship W3120630806A5019490903 @default.
- W3120630806 hasAuthorship W3120630806A5022379264 @default.
- W3120630806 hasAuthorship W3120630806A5024447718 @default.
- W3120630806 hasAuthorship W3120630806A5025385905 @default.
- W3120630806 hasAuthorship W3120630806A5036202060 @default.
- W3120630806 hasAuthorship W3120630806A5041651603 @default.
- W3120630806 hasAuthorship W3120630806A5049655890 @default.
- W3120630806 hasAuthorship W3120630806A5050859911 @default.
- W3120630806 hasAuthorship W3120630806A5053583356 @default.
- W3120630806 hasAuthorship W3120630806A5064047605 @default.
- W3120630806 hasAuthorship W3120630806A5067042263 @default.
- W3120630806 hasAuthorship W3120630806A5069122156 @default.
- W3120630806 hasAuthorship W3120630806A5080750886 @default.
- W3120630806 hasAuthorship W3120630806A5081704353 @default.
- W3120630806 hasAuthorship W3120630806A5081967303 @default.
- W3120630806 hasBestOaLocation W31206308061 @default.
- W3120630806 hasConcept C104317684 @default.
- W3120630806 hasConcept C120665830 @default.
- W3120630806 hasConcept C121332964 @default.
- W3120630806 hasConcept C126322002 @default.
- W3120630806 hasConcept C159047783 @default.
- W3120630806 hasConcept C191093355 @default.
- W3120630806 hasConcept C193252679 @default.
- W3120630806 hasConcept C2777914695 @default.
- W3120630806 hasConcept C2779489039 @default.
- W3120630806 hasConcept C523546767 @default.
- W3120630806 hasConcept C54355233 @default.
- W3120630806 hasConcept C61511704 @default.
- W3120630806 hasConcept C71924100 @default.
- W3120630806 hasConcept C86803240 @default.
- W3120630806 hasConcept C89423630 @default.
- W3120630806 hasConceptScore W3120630806C104317684 @default.
- W3120630806 hasConceptScore W3120630806C120665830 @default.
- W3120630806 hasConceptScore W3120630806C121332964 @default.
- W3120630806 hasConceptScore W3120630806C126322002 @default.
- W3120630806 hasConceptScore W3120630806C159047783 @default.
- W3120630806 hasConceptScore W3120630806C191093355 @default.
- W3120630806 hasConceptScore W3120630806C193252679 @default.
- W3120630806 hasConceptScore W3120630806C2777914695 @default.
- W3120630806 hasConceptScore W3120630806C2779489039 @default.
- W3120630806 hasConceptScore W3120630806C523546767 @default.
- W3120630806 hasConceptScore W3120630806C54355233 @default.
- W3120630806 hasConceptScore W3120630806C61511704 @default.
- W3120630806 hasConceptScore W3120630806C71924100 @default.
- W3120630806 hasConceptScore W3120630806C86803240 @default.
- W3120630806 hasConceptScore W3120630806C89423630 @default.
- W3120630806 hasIssue "Supplement_1" @default.
- W3120630806 hasLocation W31206308061 @default.
- W3120630806 hasLocation W31206308062 @default.
- W3120630806 hasLocation W31206308063 @default.
- W3120630806 hasOpenAccess W3120630806 @default.
- W3120630806 hasPrimaryLocation W31206308061 @default.
- W3120630806 hasRelatedWork W11041137 @default.
- W3120630806 hasRelatedWork W13323693 @default.
- W3120630806 hasRelatedWork W1344893 @default.
- W3120630806 hasRelatedWork W13508855 @default.
- W3120630806 hasRelatedWork W16201808 @default.
- W3120630806 hasRelatedWork W2075626 @default.
- W3120630806 hasRelatedWork W5030754 @default.
- W3120630806 hasRelatedWork W576501 @default.
- W3120630806 hasRelatedWork W7393739 @default.
- W3120630806 hasRelatedWork W13612379 @default.
- W3120630806 hasVolume "7" @default.
- W3120630806 isParatext "false" @default.
- W3120630806 isRetracted "false" @default.
- W3120630806 magId "3120630806" @default.
- W3120630806 workType "article" @default.